Results 161 to 170 of about 77,484 (271)

Socioeconomic Health Disparities in the Treatment of Thyroid Cancer: A Single Institution in Southwestern Ohio

Head &Neck, Volume 48, Issue 8, Page 2114-2119, August 2026.
ABSTRACT Background Disparities in thyroid cancer care are driven by demographic and socioeconomic factors such as insurance status, income, and access to specialized care. Methods Retrospective chart review. Demographic and clinical data from 281 adult patients who underwent thyroidectomy or hemithyroidectomy for papillary or follicular thyroid cancer
Breanna Dominguez, Aurora Moberly, Nga Tran, Timothy Crawford, Sameep Kadakia, Mac Kenzie Reece   +5 more
wiley   +1 more source

The Role of Thyroidectomy in the Management of Thyroglossal Duct Carcinoma: A Systematic Review

Otolaryngology–Head and Neck Surgery, Volume 175, Issue 2, Page 271-280, August 2026.
Abstract Objective The extent of surgical management of thyroglossal duct‐associated differentiated thyroid carcinoma remains controversial. This study aims to evaluate the role of total thyroidectomy in patients with thyroglossal duct‐associated differentiated thyroid carcinoma and provide insights to support individualized, evidence‐based care.
Hidde H. IJtsma, Sam P. J. van Dijk, Carrie E. Cunningham, Folkert J. van Kemenade, Robin P. Peeters, Stijn Keereweer, Tessa M. van Ginhoven   +6 more
wiley   +1 more source

Clinical Applications of Multimodal Artificial Intelligence in Otolaryngology: A State‐of‐the‐Art Review

Otolaryngology–Head and Neck Surgery, Volume 175, Issue 2, Page 304-315, August 2026.
Abstract Objective Artificial intelligence (AI) has advanced to simultaneously process visual, auditory, and textual inputs, providing users with “multimodal” AI. Given the clinical integration potential of these tools, otolaryngologists must stay informed. This study reviews current literature on applications of multimodal AI in otolaryngology.
Ying Jie Li, Flora Su, Norbert Banyi, Philip Edgcumbe, Andrew Thamboo, Ameen Amanian   +5 more
wiley   +1 more source

The Molecular Heterogeneity of NRAS Variants in Thyroid Nodules

Otolaryngology–Head and Neck Surgery, Volume 175, Issue 2, Page 343-349, August 2026.
Abstract Objective NRAS variants are the most common mutations in thyroid nodules with (B)ethesda III/IV cytology. This study aims to characterize co‐occurring variants, molecular signatures, and hallmarks of cancer pathways in nodules with NRAS variants. Study Design Retrospective database analysis.
Emma De Ravin, Mohammed Alshalalfa, Ruochen Jiang, Yangyang Hao, Joshua P. Klopper, Elizabeth Cottrill   +5 more
wiley   +1 more source

Concurrent Hashimoto's Encephalopathy and Papillary Thyroid Carcinoma: A Case Report

Clinical and Experimental Neuroimmunology, Volume 17, Issue 3, August 2026.
ABSTRACT Background Hashimoto's encephalopathy (HE) is a rare steroid‐responsive autoimmune syndrome. Although HE is associated with anti‐thyroid antibodies, its concurrence with malignant thyroid tumors has rarely been described and its clinical implications remain poorly understood.
Ryo Hara, Toshiyuki Kakumoto, Anna Suzuki, Satoshi Yamashita, Takayoshi Niwa, Kanako Hayashi, Arisa Morizono, Ayaka Sato, Masahiko Tanabe, Noritaka Kudo, Masashi Hamada, Wataru Satake, Tatsushi Toda   +12 more
wiley   +1 more source

Validating the 2022 WHO classification in thyroid carcinomas: Prospective evidence for predicting iodine resistance

Histopathology, Volume 89, Issue 2, Page 251-261, August 2026.
This study assessed the 2022 WHO classification for predicting RAIR disease in thyroid carcinomas, comparing it to older classifications. In a retrospective study of 253 cases, we found the 2022 classification more effective, especially by identifying high‐grade carcinomas and tumour necrosis as critical predictive factors.
Elise André, Laurine Mebarki, Mirela Ilie, Fabien Subtil, Claire Bournaud, Françoise Borson‐Chazot, Françoise Descotes, Jean‐Christophe Lifante, Mireille Bertholon‐Grégoire, Hélène Lasolle, Myriam Decaussin‐Petrucci   +10 more
wiley   +1 more source

PRECISE: A Prognostic Thyrocyte-Derived Gene Signature for Papillary Thyroid Carcinoma. [PDF]

Clin Cancer Res
Li S, Wu CC, Marczyk VR, Loberg MA, Thennavan A, Tarabichi M, Xu L, Henderson YC, Martin ME, Tran TM, Duose DY, Sanchez-Espitia A, Luthra R, Sheng Q, Xu GJ, Huang EC, Hofmann MC, Zhao X, Lai SY, Hosseini SM, Williams MD, Wang W, Hamidi S, Zafereo ME, Cabanillas ME, Navin NE, Weiss VL, Wang JR.   +27 more
europepmc   +1 more source

Identification of Papillary Thyroid Carcinoma in Indeterminate Nodules. [PDF]

Radiol Imaging Cancer
Dou Y, Xiang Z, Song H, Wang Y, Li S, Wu P.   +5 more
europepmc   +1 more source

FOXA1 is a highly sensitive diagnostic marker for prostate cancer including small cell carcinoma of the prostate

Histopathology, Volume 89, Issue 2, Page 240-250, August 2026.
FOXA1 is a highly sensitive diagnostic marker for prostate cancer. Besides prostatic adenocarcinoma, it is also expressed in 57%–80% of metastatic or primary prostatic small cell carcinomas, which lose traditional prostatic markers including NKX3.1. Although it is less specific than NKX3.1, it can serve as a valuable adjunct for confirming prostatic ...
Jianping Zhao, Jun Yao, Hossein Hosseini, Ezra Baraban, Ruihe Lin, Charles C. Guo, Lei Huo, Wei Lu, Khaja Khan, Shufang Wang, Luisa Maren Solis Soto, Qingqing Ding   +11 more
wiley   +1 more source

CD8+ T cells in Hashimoto's thyroiditis-associated papillary thyroid carcinoma. [PDF]

Eur Thyroid J
Wang L, Zhang L, Chen J, Wang D, Zhang Y, Sun L, Su W, Li M, Zhou Q, Wang J, Jiang J.   +10 more
europepmc   +1 more source